Intercept Pharmaceuticals, Inc.(NASDAQ : ICPT)
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
Health Technology » Pharmaceuticals Other
|VRX||Valeant Pharmaceuticals International, Inc.||3.27%||29.07||14.1%||$171.05m|
|JAZZ||Jazz Pharmaceuticals Plc||0.57%||179.17||2.2%||$142.15m|
|HZNP||Horizon Therapeutics Plc||5.02%||92.14||5.5%||$124.53m|
|BHC||Bausch Health Cos., Inc.||3.27%||29.07||0.0%||$91.68m|
|SAVA||Cassava Sciences, Inc.||8.31%||40.92||0.0%||$55.78m|
|UTHR||United Therapeutics Corp.||2.12%||197.87||14.0%||$55.65m|
|PRGO||Perrigo Co. Plc||1.80%||45.82||6.9%||$49.71m|
|SAGE||SAGE Therapeutics, Inc.||2.03%||70.86||7.6%||$33.60m|
|PCRX||Pacira Biosciences, Inc.||1.22%||62.21||9.9%||$30.64m|
|AXSM||Axsome Therapeutics, Inc.||-2.68%||58.42||1.9%||$26.79m|
|RVMD||Revolution Medicines, Inc.||4.07%||31.99||0.0%||$23.38m|
Intercept Pharmaceuticals, Inc. operates as a biopharmaceutical company. The firm engages in the research, development and commercialization of novel therapeutics in treating chronic liver diseases. Its product pipeline includes OCALIVA which is used for the treatment of biliary cholangitis, nonalcoholic steatohepatitis, sclerosing cholangitis and biliary atresia. The company was founded by Mark E. Pruzanski and Roberto Pellicciari on September 4, 2002 and is headquartered in New York, NY.